Full Text View
Tabular View
No Study Results Posted
Related Studies
A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule(SPIRIT—DZSM-2)
This study is not yet open for participant recruitment.
Verified by Guangzhou University of Traditional Chinese Medicine, October 2007
First Received: October 22, 2007   Last Updated: October 28, 2007   History of Changes
Sponsored by: Guangzhou University of Traditional Chinese Medicine
Information provided by: Guangzhou University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier: NCT00547950
  Purpose

In order to observe the influence of the Dengzhan Shengmai Capsule on the endpoint of patients with ischemic stroke, we hold the multi-centered prospective cohort study. From November 2007 to December 2009, 12000 subjects are included in 200 clinical research centers all over China. The subjects naturally formed two cohorts based on taking Dengzhan Shengmai capsule or not. The basic therapy included antiplatelet aggregation , stroke health education, management of blood pressure, blood lipid and blood glucose, etc. Then all of the subjects are visited on the 360th day after inclusion. The recurrence of stroke, cardiovascular events, and peripheral arterial events are observed.


Condition Intervention
Ischemic Stroke
Drug: :Deng Zhan Sheng Mai Capsule

U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Parallel Assignment
Official Title: A Model Study on the Comprehensive Treating Protocol of Secondary Prevention and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine

Further study details as provided by Guangzhou University of Traditional Chinese Medicine:

Primary Outcome Measures:
  • recurrence of stroke [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Cardiovascular events and other peripheral vascular events Modified Rankin Scale (mRS) [ Time Frame: 1 year ]

Estimated Enrollment: 12000
Study Start Date: November 2007
Estimated Study Completion Date: October 2009
Arms Assigned Interventions
1: Experimental
drug
Drug: :Deng Zhan Sheng Mai Capsule
capsule,0.18g,2#,po,Bid*1year.

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 40-75 years old
  • Ischemic stroke diagnosed by CT/MRI scan
  • Patient presenting from 14 days to 6 months of first onset of Ischemic stroke.
  • Presence of at least one risk factor of stroke (such as hypertension, Diabetes mellitus, coronary heart disease, hyperlipidemia, and smoking, etc.)that can be interfered in.
  • Informed consent.

Exclusion Criteria:

  • Silent cerebral infarction;
  • Patients after vasculoplasty with Intracranial Artery Stenosis.
  • Watian drinking test≥grade 4.
  • MRS=grade 5.
  • Cerebral infarction due to other causes except arterial Sclerosis(i.e. cardiogenic embolism, arteritis, polycythemia vera, primary thrombocythemia, sickle-cell anemia,, thrombotic thrombocytopenia purpura, DIC, cerebral amyloid angiopathy, Moyamoya disease, intracranial vascular malformations etc);
  • Presence of serious heart disease, heart, liver, lung, and kidney functional failure; malignancy; alimentary tract hemorrhage;
  • Patients with mental disorder.
  • Patients that cannot take medicine due to other causes
  • Females during pregnancy or lactation.
  • Already attend other clinical trial.
  • That unsuitable for clinical trial.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00547950

Contacts
Contact: Yan Huang, Bachelor (08620) 81887233 ext 34530 huang61@medmail.com.cn
Contact: LIxin Wang, Doctor (08620) 81887233 ext 34530 plawlx@126.com

Locations
China, Guangdong
Guangdong Province Hospital of Tradtional Chinese Medicine
Guangzhou, Guangdong, China, 510120
Sponsors and Collaborators
Guangzhou University of Traditional Chinese Medicine
Investigators
Principal Investigator: Yan Huang, Bachelor Guangdong Province Hospital of Tradtional Chinese Medicine
  More Information

No publications provided

Study ID Numbers: 2006BAI04A02-2
Study First Received: October 22, 2007
Last Updated: October 28, 2007
ClinicalTrials.gov Identifier: NCT00547950     History of Changes
Health Authority: China: Ethics Committee;   China: Ministry of Health;   China: State Food and Drug Administration

Study placed in the following topic categories:
Cerebral Infarction
Stroke
Vascular Diseases
Neoplasm Metastasis
Central Nervous System Diseases
Ischemia
Brain Diseases
Cerebrovascular Disorders

Additional relevant MeSH terms:
Pathologic Processes
Nervous System Diseases
Stroke
Vascular Diseases
Central Nervous System Diseases
Cardiovascular Diseases
Ischemia
Brain Diseases
Cerebrovascular Disorders

ClinicalTrials.gov processed this record on May 07, 2009